Renaissance Technologies's CDTX Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 110,560 shares of Cidara Therapeutics, Inc. (CDTX) worth $24.42 M, representing 0.04% of the portfolio. First purchased in 2024-Q2, this short-term holding has been held for 7 quarters.
Based on 13F filings, Renaissance Technologies has maintained this position in CDTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 64,260 shares. Largest reduction occurred in Q3 2025, reducing 52,517 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Cidara Therapeutics (CDTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cidara Therapeutics (CDTX) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2024 | +95,517 | New Buy | 95,517 | $11.94 |
| Q3 2024 | +2,300 | Add 2.41% | 97,817 | $10.75 |
| Q4 2024 | -2,200 | Reduce 2.25% | 95,617 | $26.88 |
| Q1 2025 | -3,100 | Reduce 3.24% | 92,517 | $21.54 |
| Q2 2025 | +64,260 | Add 69.46% | 156,777 | $48.71 |
| Q3 2025 | -52,517 | Reduce 33.50% | 104,260 | $95.76 |
| Q4 2025 | +6,300 | Add 6.04% | 110,560 | $220.89 |
Renaissance Technologies's Cidara Therapeutics Investment FAQs
Renaissance Technologies first purchased Cidara Therapeutics, Inc. (CDTX) in Q2 2024, acquiring 95,517 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Cidara Therapeutics, Inc. (CDTX) for 7 quarters since Q2 2024.
Renaissance Technologies's largest addition to Cidara Therapeutics, Inc. (CDTX) was in Q2 2024, adding 95,517 shares worth $1.14 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 110,560 shares of Cidara Therapeutics, Inc. (CDTX), valued at approximately $24.42 M.
As of the Q4 2025 filing, Cidara Therapeutics, Inc. (CDTX) represents approximately 0.04% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Cidara Therapeutics, Inc. (CDTX) was 156,777 shares, as reported at the end of Q2 2025.